EnWave Corp (TSX-V:ENW, OTC:NWVCF, FRA:E4U) earlier this week announced a new agreement involving Swiss Cannabis Selection and Schibano Pharma, marking another step in the company's renewed push into the cannabis processing sector.
Speaking with Proactive, chief executive Brent Charleton said interest in EnWave's technology has been increasing following the collection of commercial-scale operating data from licensed cannabis producers in Canada.
Charleton explained that EnWave's proprietary REV technology has demonstrated the ability to significantly reduce cannabis drying times while maintaining product quality. He reported that the company had been able to prove the technology could "reduce drying times from between 2 and 5 days for all cultivars, without damaging any of the cannabinoid content."
Under the new arrangement, Swiss Cannabis Selection and Schibano Pharma will evaluate a 10kW REV unit in Switzerland over the coming months. The trial is intended to assess the technology's performance in a medical cannabis production environment. If successful, the initiative could lead to the purchase of a large-scale GMP machine within the next year.
Charleton noted that Schibano Pharma's focus is on producing medical-grade cannabis for therapeutic use across legal European jurisdictions, highlighting the growing importance of quality assurance and production efficiency within the sector.
A key catalyst for EnWave is the potential conversion of the trial into a commercial machine sale. Successful validation of the Canadian operating data in a European pharmaceutical environment could support broader adoption of REV technology among medical cannabis producers.
Another potential catalyst is the apparent resurgence of interest from cannabis operators. Charleton said the sector had been relatively quiet following the challenges faced by many producers after cannabis legalization in Canada. However, recent performance data appears to be driving renewed engagement from prospective customers.
The economic benefits outlined by management could also support future sales activity. Charleton explained that licensed production space is highly valuable and that reducing the footprint required for traditional drying processes can improve operational efficiency. He suggested that producers could increase throughput while lowering production costs, provided product quality remains consistent or improves.
As the Swiss trial progresses, investors will likely be watching for evidence that the technology can deliver similar results in Europe, potentially opening the door to additional commercial opportunities in the medical cannabis market.